View in EDS HTML Full Text PDF Full Text

Clinical Laboratory Parameters in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52 in the Phase 3 ECZTRA 6 Trial.

Saved in:
Bibliographic Details
Title: Clinical Laboratory Parameters in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52 in the Phase 3 ECZTRA 6 Trial.
Authors: Paller AS; Walter J. Hamlin Professor of Dermatology and Chair, Departments of Dermatology and Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. apaller@northwestern.edu., Cork MJ; Sheffield Children's NIHR Commercial Research Delivery Centre, Sheffield, UK.; Sheffield Dermatology Research, Division of Clinical Medicine, University of Sheffield Medical School, Sheffield, UK., Hong HC; Department of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada., Soong W; AllerVie Health-Alabama Allergy & Asthma Center, Birmingham, AL, USA., Schneider SKR; LEO Pharma Inc., Madison, NJ, USA., Lo H; LEO Pharma Inc., Madison, NJ, USA., Vinther F; LEO Pharma A/S, Ballerup, Denmark., Thøgersen P; LEO Pharma A/S, Ballerup, Denmark., Wollenberg A; Department of Dermatology and Allergy, Augsburg University Hospital, Augsburg, Germany.; Department of Dermatology and Allergy, Ludwig Maximilian University of Munich, Munich, Germany.; Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany.
Source: Dermatology and therapy [Dermatol Ther (Heidelb)] 2026 Jun; Vol. 16 (6), pp. 3037-3048. Date of Electronic Publication: 2026 Apr 25.
Publication Type: Journal Article
Journal Info: Publisher: Springer Healthcare Communications Country of Publication: Switzerland NLM ID: 101590450 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8210 (Print) NLM ISO Abbreviation: Dermatol Ther (Heidelb) Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2193-8210
DOI:10.1007/s13555-026-01745-7